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Summary: There are three different test generations of enzyme-linked immunosorbent assays (ELISA) for the
detection of human immunodeficiency virus (HIV) infection, depending on whether virus lysate, recombinant
proteins or synthetic peptides are used äs solid phase antigen. Four different assays, i. e., three sandwich
ELISAs and one competitive test, were used to demonstrate differences between the three Systems with regard
to the content of different diagnostically relevant virus proteins. The sensitivities and specificities of these
assays were compared by using 312 anti-HIV positive sera and 500 sera of healthy blood donors. The highest
sensitivity and specificity were achieved by the competitive ELISA based on recombinant proteins, and by
the sandwich ELISA based on synthetic peptides.
Introduction
The most common screening method for the diagnosis
of infection with human immunodeficiency virus
(HIV) is the detection of virus-specific antibodies by
sandwich ELISA. There are three different test gen-
erations, which differ with respect tö the insolubilized
antigen used:
The assays of the first generation are based on the
adsorption of purified lysed virus cultivated in im-
mortalized human lyrriphocytes. The quantitative ra-
tios between the virus proteins are difficult to repro«
duce from one preparation to the other. In addition,
diagnostically relevant virus proteins, such äs env-
gene-derived products, are often not available in suf-
ficient quantities (1). On the other hand, host cell
proteins incorporated in the virus membrane cannot,
or can only incompletely, be removed (2). Antibodies
to HLA-DR antigens may therefore produce false-
positive resülts (3), especially in patients with autoim-
mune disorders or in multiparae (4). The sensitivity
of these tests ranges from 97.2% to 100%, their
specificity from 70% to 100% (5).
To circumvent these problems, the assays of the sec-
ond generation use recombinant proteins äs antigen.
The composition of the antigen used for insolubili-
zation is now reproducible and can be selected ac-
cording to the diagnostic relevance of the virus pro-
teins. These proteins, however, require an extensive
purification to avoid false positive reactions.
Synthetic peptides used äs antigens in third generation
tests permit the binding of exclusively specific im-
munodominant sequences to the solid phase. The
reduction of a great number of reactive epitopes of
the virus to a few or just one sequence requires a
detailed epitope mapping (6). The peptide used in the
test has to represent a region, which
(i) induces an antibody response in all HlV-infected
persons,
(ii) provokes an antibody response äs early äs pos-
sible,
(iii) maintains the antibody response over all the
stages of the disease (7).
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Materials and Methods
Sol id phase
The tests of the first generation werc performed using com-
mercial microtitre plates of the anli-HTLV III ELISA (Ortho
Diagnostic Systems, New Jersey, USA) and polystyrene micro-
titre plates (Polyplast, Halberstadt, Germany) coated with pur-
ified lysed virus grovvn in H9 cells s described in delail eise-
where (8). The same plates were also used for the tests of the
second and third generations. The respeclive antigens dissolved
in 100 μΐ of 0.1 mol/1 carbonate buffer, pH 9.5, were added to
each well for adsorption over 16 —20 h at 4 °C.
The antigens used in the second test generation were two highly
purified recombinant env-proteins of HIV-1. For the competi-
tive test wc used a glycosylated gp!60 expressed in verocells
(Immuno-AG, Vienna, Austria) adjusted to a concentration of
10 rag/1. For the Sandwich ELISA, the solid phase was coated
with 20 mg/1 of a -galactosidase-gp41 fusion prolein expressed
in E. coli (rlacZgp41) (Schuhen et al.. in preparation).
The peptide used s antigen in the third generation assay
corresponds to the sequence aa 595 — 620 of the transmembrane
protein gp 41 of HIV-1. For adsorption, the peptide was used
in a concentration of 10 mg/1. After coating, free binding sites
of the solid phase were blocked with sheep serum (200 ml/l) in
0.01 mol/1 phosphate buffer, 0.15 mol/1 NaCl for 60 min at
room temperature. Prior to use, all coated plates were washed
twice with 0.01 mol/1 phosphate buffer, pH 7.2, 0.3 mol/1 NaCl,
l ml/l Tween 20.
The aim of this study was to determine the degree of certainty
for the detection of HIV infection, using different assay prin-
ciples and different solid phase antigens containing an inunu-
nodominant region of the transmembrane protein gp41. Other
Parameters influencing the assay quality were optimized for
each assay.
Q u a n t i t a t i v e sol id-phase analysis of several gene
products
Plates of the first generation test were analysed for their relative
content of 5 selected env- and gag-gene products. Polyclonal
antisera from sheep to the HIV-1 proteins p!5, p!7, p24, gp41
and gpl20 (Biochrom KG, Berlin) were applied in twofold
serial dilutions, starting with a concentration of 20 mg/1, to
detect the bound proteins. The dilution medium used in all the
Steps of the assays was phosphate/NaCl/Tween, 100 ml/l Ge-
lafusal (Serumwerk, Bernburg). One hundred μΐ of the different
dilutions were incubated in the virus-sensitized wells for l h at
37 °C.
After this incubation, the wells were washed five times with
phosphate/NaCl/Tween lo remove any unbound reagents. One
hundred μΐ of horseradish peroxidase-labelled anti-sheep IgG
adjusted to an IgG concentration of 0.3 mg/1 were added to the
wells and incubated for l h at 37 °C.
After a further washing, the Substrate reaction was performed
using 100 μΐ of 5.5 mmol/l o-phenylenediamine and 8.5 mmol/1
H2O2 in 0.1 mol/1 citrate buffer, pH 5.0. This reaction was
stopped after 10 min by addition of 100 μΐ of 2 mol/1 H2SO4,
0.05 mol/1 sodium sulphite. The absorbances were read bi-
chromalically al 492 nm and 690 nm (10).
The relative quantity of the selected virus proteins adsorbed to
the solid phase was expressed s a percentage of maximal
adsorption at Saturation, s determined from the maximal ab-
sorbance values of the ELISA titration curves.
Quan t i t a t i ve solid phase analysis of an i m m u n o -
d o m i n a n t epi tope
The solid phases coated with the different antigens were ex-
amined for the presence of a diagnostically relevant immuno-
dominant region of the transmcnbranc prolein gp41 (aa 606—
620). This region is the binding site of the human monoclonal
antibody CB-HIV-l-gp41 (9), which was applied on twofold
serial dilutions starting with a concentration of 20 mg/1. The
antibody Solutions were incubated for l h at 37 °C in the coated
wells. After the solid phase had been washed five times with
phosphate/NaCl/Tween, an horseradish peroxidase-labelled
anti-human IgG adjusted to an IgG concentration of 0.05 mg/
l was incubated for l h at 37 °C. Unoound reagents were re-
moved by washing. After the Substrate reaction, the absorb-
ances were read s described above.
Serum react ivi ty
To document the relationship of the absorbance values pro-
duced in the ELISAs by reactive and non-reactive serurn sam-
ples (P/N ratio), titrations were performed on anti-HIV positive
(n = 20) and anti-HIV negative (n = 20) pooled serurn samples,
using twofold serial dilutions, and starting with the undiluted
serum. One hundred μΐ of these samples were incubated in the
wells of all the test Systems for l h at 37 °C. The wells were
washed, and the horseradish peroxidase-labelled anlKhuman
IgG (0.05 mg/1) was incubated for l h at 37 °C.
Sandwich ELISA of the first generation
For the first generation test developed in our laboratory, 55 μΐ
of the l: 51 diluted serum samples were incubated for l h at
37 °C followed by five washes and a l h incubation of 100 μΐ
horseradish peroxidase labelled anti-human. IgG (IgG: 0.2 mg/1)
per well at 37 °C. Another washing was followed by a 30 min
Substrate reaction.
Sandwich ELISA of the second generation
The sandwich principle was also applied in the test of the second
generation, using the purified, insolubilized, recombinant
rlacZgp41 protein. One hundred μΐ of the l: 150 diluted serum
samples were incubated for l h at 37 °C. After washing the
plates five times with phosphate/NaCl/Tween, an horseradish
peroxidase-labelled anti-human IgG adjusted to an IgG con-
centration of 0.05 mg/1 was incubated for l h at 37 °C. This
was followed by a 15 min reaiction with the above-described
Substrate sohition.
Competitive ELISA of the second generation
In this assay, antibodies to an immunodominant region of the
transmembrane protein gp41 of HIV-1 in the serum of HIV-
infected persons inhibit the binding of the horseradish peroxi-
dase-labelled human monoclonal antibody CB-HIV-l-gp41 to
the insolubilized recombinant gp 160 protein (11). Twenty five
μΐ of the undiluted serum samples were incubated for 45 min
at 37 °C with 75 μΐ of the horseradish peroxidase-labelled mono?
clonal antibody adjusted to a concentration of 6.5 mg/I. The
wells were washed five times with phosphate/NaCl/Tween, fol-
lowed by a 10 min Substrate reaction.
Sandwich ELISA of the third generation
One hundred μΐ of the l: 10 diluted serum samples were incu-
bated in the peptide-coated wells for l h at 37 °C. After incu^
bation the wells were washed five times and the anti-human
IgG-horseradish peroxidase conjugate, adjusted to a concentra-
tion of 0.05 mg/1, was added and incubated for l h at 37 °C.
Another washing was followed by a 10 min Substrate reaetion.
Serum samples
Three hundred and twelve anti-HIV-1 positive serum samples
from HIV-1 infected persons at all stages of the disease (CDC
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classification II— IV), including 200 serum samples from AIDS
patients (partially trcated with azidothymidine), and 500 sera
from anli-HIV negative healthy blood donors were investigated.
The serum sampJes were kindly provided by five different clini-
cal or screening cenlres. All the anti-HIV positive sera were
confirmed by immunoblotting.
S t a t i s t i c a l me thods
For each test System the cut-ofT value was defined äs the mean
value derived from at least 100 anti-HIV negative samples plus
the threefold Standard deviation (SD). In presenting the results
of the competitive assay, a value equivalent to 3 SD was
subtracted.
The sensitivity of each test System is defined äs the proportion
of positive test results obtained when a population of true
positives is tested, and the specificity of each test System äs the
frequency of negative results obtained when a population of
true negatives is lested.
Samples that gave false negative and false positive results in
the ELISAs were retested by immunoblotting.
Results
Epitope analysis and serum reactivity
The relative quantity of reactive env- and gag-gene
products of the solid phase adsorbed virus proteins is
shown in figure l. The ratio of the immunologically
reactive gag-to env-gene products is about 6:1.
gp120
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p 24
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p 24
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p17
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Fig. l. Relative proportion of 5 gag^ and env-proteins adsorbed
to the solid phases in the anti-HTLV-III ELISA (Ortho
Diagnostic Systems) (Part A) and in the self-made anti-
HIV ELISA (Part B) on the solid phase adsorbed pro-
teins.
Curves for the titration of the humari monoclonal
antibody, CB-HIV-l-gp41, to the immunodominant
region of the transmenbrane protein gp41 of HIV-1
with the fespective insolubilized antigens is shown in
figure 2. The absorbance pläteaus, which reflect the
excess of antibodies available for binding tö the lim-
ited quantity of gp41 of the respective insolubilized
antigen, characterize the different epitope density on
the solid phase. Insolubilization of the peptide (amino
acids 959-620) led tö the highest epitope density; the
next highest epitope density was found for the inso-
2,5l
2.0
M.5
0,5
0,0
20.0 10.0 5.0 2.5 1.25 0.62 0.31 0.16 0.08 0.03
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Fig. 2. Titration curves of a human monoclonal antibody in
first (I), second (II a: rlacZgp41; II b: rgploO) and third
(III) generation tests.
The different absorbance pläteaus are representative for
the limiled quantity of the immunodominant transmem-
brane protein, gp41, in each test System.
r 100
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Fig. 3. Dependence of P/N ratio on the serum dilution; relation
of serum reactivity of the anti-HIV-positive and -ne-
gative pooled sera (n = 20) in the first (I), second (II a:
r!acZgp41; II b: rgploO) and third (III) generation tests.
lubilized recombinant antigens. As deduced from the
absorbance values, the relative quantity of reactive
epitopes from this region of the transmembrane pro-
tein in the absorbed virus lysate is no greater than
8% and in the adorbed recombinant proteins 60% of
the adsorbed peptide epitope density (100%).
Figure 3 shows the P/N ratios obtained from testing
the anti-HIV-positive and -negative pooled sera, de-
pending on their dilutions.
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Fig. 4. Frequency distribution of the absorbances produced by
312 anti-HIV-positive (black) and 500 negative (white)
serum samples in the sandwich-type ELISA of the first
generation with virus lysate (a), of the second generation
with purified recombinant rlacZgp41-protein (b) and of
the third generation with peptides (c).
The increase in P/N ratios with growing serum dilu-
tion is due to reduced unspecific binding of human
IgG from the serum samples. The extent of unspecific
IgG binding of anti-HIV-negative serum samples
clearly depends on the antigen used fpr solid phase
adsorption. Thus a 30-fold seruin dilution resulted in
a P/N-ratio of about 30 when the gp41 peptide was
used äs the solid phase antigen in the Sandwich
ELISA. Using purified recombinant gp41 protein äs
solid phase antigen in the same assay, a P/N ratio of
about 30 was obtained with a 250-fold serum dilution.
Serum testing
The frequency distributions of the absorbances of the
anti-HIV-positive and -negative serum samples, äs
determined in the three different Sandwich ELISAs,
are shown in figure 4.
The clearest differentiation was obtained in the third
generation assay, using insolubilized peptide.
The second generation sandwich ELISA does not
allow an unequivocal differentiation of the two groups
of serum samples. Using the chosen cut-off value, 8
semm samples were determined äs false positive and
9 äs false negative, äs deduced from the Western blot
results.
The competitive test of the second generation also
clearly discriminated between the anti-HIV antibody-
positive and -negative sera (flg. 5).
Two of the anti-HIV-positive sera, which did not react
in the first-generation sandwich-ELISA, proved to be
unequivocally positive in the immunoblot (fig. 6). The
absorbances of these two sera produced in the differ-
ent tests are listed in table l.
The cut-off values, the sensitivity and the specificity
of each of the four test Systems are shown in table 2.
90 80 70 60 50 40 30 20
Inhibition of binding [%]
10
„Fig. 5. Inhibition of binding of 102 anti-HIV-positive (black)
and -negative (white) serum,samples in a coiiipetitive
assay of the second generatJQn.
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Fig. 6. Western blot precipitation patterns of serum samples
from an early phase of infection from two asymptomalic
HlV-infected persons (6a — serum 124; 6b — serum
293).
The left lanes in a and b are the respective positive
controls.
Tab. 1. Single determinations of two anti-HIV-positive sera in
the four test Systems
Test Cut-off Serum 124 Serum 293
First
generation
Second
generation
Third
generation
Competitive
assay
0.42
(absorbance)
0.40
(absorbance)
0.35
(absorbance)
30%
(Inhibition)
0.257
(negative)
0.460
(positive)
0.811
(positive)
92.4%
(positive)
0.184
(negative)
0.329
(negative)
0.637
(positive)
97.3%
(positive)
Tab. 2.' Cut-off values, sensitivity and specificity of the four
test Systems
Test CuUoff Specificity Sensitivity
First
generation
Second
generation
Third
generation
Competitive
assay
0.42
(absorbance)
0.40
(absorbance)
0.35
(absorbaoce)
30%
(Inhibition)
100%
98.4%
100%
100%
99.4%
97.2%
100%
100%
Discussion
Env-gene products of HIV induce an immune re-
sponse preceding that to gag-gene products (12). In
contrast to the latter response, the immune response
to env-gene products of HIV remains relatively con-
stant up to the stage of AIDS (CDC, stage IV) (13,
14,15). For this reason, tests employing a preferential
detection of antibodies to env-proteins are more sen-
sitive (16). The quantities of these diagnostically rele-
vant proteins used in the solid phase of the first
generation assays are generally too low. The compo-
sition of HIV proteins was very similar in both kinds
of investigated ELISA plates that use adsorbed puri-
fied virus used äs antigen. But the content of the env-
gene products in relation to the total amount of
insolubilized virus proteins is less then 15%, äs shown
by the fact that pol-gene derived products were not
detected in the investigations described due to a lack
of antibodies to reverse transcriptase and protease.
The human monoclonal antibody, CB-HIV-l-gp41,
was foimd to recognize an immunodominant region
on the transmembrane protein, gp41 (17). Investiga-
tions with this antibody have shown that the density
of its target epitope can be systematically increased
from the first to the third generation assay.
This is also the reason for the different reactivities of
1
 the two serum samples, which were clearly positive in
the Sandwich ELISA only when peptide is used äs
solid phase antigen. This result is in excellent agree-
ment with their precipitation profile in the Western
blot. Both samples reacted poorly with the gag-gene-
derived proteins, p!7 and p24, representing the ma-
jority of solid phase-adsorbed proteins in the first
generation assay.
The P/N ratios of the screening ELISAs, depending
on the serum dilution, are of prime importance for
their specificity and sensitivity. A high P/N-ratio of
low serum dilutions was obtained only when peptides
were used äs solid phase antigen. In the case of ad-
sorbed virus lysate or recombinant proteins, undesir-
able reactions of IgG with co-immobilized host-cell
or host-bacterial compounds decreased the P/N-ratio.
The insufficient sensitivity and specificity of the sand-
wich ELISA based on the recombinant protein is due
to the insufficient purification of the gp41 protein,
which still contains material that reacts with anti-£.
coli antibodies present in the serum of blood donors.
By dilution sera in medium containing E. coli lysate,
it was shown unequivocally that positive results can
be caused by antibodies to E. coli (data not shown).
Even highly purified recombinant proteins contain
epitopes likely to react with IgG molecules which are
not directly involved in the immune response to HIV
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(15). Thcrelorc, first and second generation tests are
recommended for higher seruni dilutions if no com-
petitive assay principle is applied.
The numbers of 312 anti-HIV antibody-positive and
of 500 anti-HIV antibody-negative sera are certainly
insufficient for a comprehensive evaluation of the
sensitivity and the specificity. Nevertheless, advan-
tages and disadvantages of the individual assay vari-
ants and the solid-phase materials used can easily be
seen from the data presented here.
In our experiments, the best differentiation between
the anti-HIV-positive and -negative serum samples
was achieved with the peptide ELISA based on only
one peptide, which agrees with the results reported
by Smith et al. (18). Although this peptide represents
a highly conserved immunogenic region (7), geo-
graphic variability, especially in proteins encoded by
the env-gene, has been shown by genetic studies (19)
on this region of the transmembrane protein. This is
reflected by different reactivities of serum samples to
peptides which differ in only one amino acid (20).
However, the low molecular mass and the high epitope
density permit a co-immobilization of different pep-
tides even together with complete proteins such äs
antibodies, so that different parameters can be selec-
tively determined in one and the same assay (21).
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